Novo Nordisk Gains EU Approval for 7.2mg Wegovy After 21% Weight Loss Data
The European Commission approved a 7.2mg once-weekly maintenance dose of Wegovy, administered as three 2.4mg injections, following Phase III data showing 21% body weight loss in 2,000 patients. Novo Nordisk has applied for a single-dose pen and targets an EU launch this year to reclaim share from Lilly’s $23bn Mounjaro.
1. EU Approval Details
The European Commission approved a new 7.2mg once-weekly maintenance dose of Wegovy for adults with obesity, administered as three consecutive 2.4mg injections. Novo Nordisk has also submitted an application for a single-dose EU pen, potentially launching this formulation before year-end.
2. Clinical Efficacy Data
Results from two Phase III trials involving 2,000 patients showed the 7.2mg dose delivered mean body weight reductions of 21%, compared with 15% average loss on the 2.4mg dosage. These findings expand efficacy options beyond existing 0.25mg to 2.4mg doses.
3. Competitive Landscape
The higher-dose approval is a strategic counter to Eli Lilly’s Mounjaro, which posted $23bn in global obesity revenue in 2025 with doses up to 15mg. Wegovy’s global sales reached $12.5bn last year, and the new dose aims to narrow this gap.
4. Outlook and Expansion Plans
Novo Nordisk recently launched an oral semaglutide obesity pill in the US, reaching 50,000 prescriptions by January 2026. Industry forecasts estimate 400,000 US prescriptions in Q1 2026, underscoring the company’s broader growth trajectory in the obesity market.